deCODE genetics

deCODE genetics is a pioneering biotechnology company based in Reykjavík, Iceland, renowned for its large-scale population genetic studies. Founded in 1996 by neurologist Kári Stefánsson, the company has leveraged the unique genetic heritage and comprehensive genealogical records of the Icelandic people to make groundbreaking discoveries linking genetic variation to common diseases. Its work has fundamentally advanced the field of human genetics and influenced the development of personalized medicine globally.

History

The company was established in 1996 by Kári Stefánsson, a former professor at Harvard University, with the ambitious goal of mining the Icelandic population's genetic data for medical insights. Its formation coincided with the rise of the Human Genome Project and significant advancements in DNA sequencing technology. In 1998, the Althing, Iceland's parliament, passed the controversial Health Sector Database Act, which aimed to create a centralized health database, a move that initially seemed to pave the way for the company's research model. Following financial difficulties, the original deCODE genetics filed for Chapter 11 bankruptcy in 2009. In 2012, the firm was acquired by Amgen, a leading biotechnology firm based in Thousand Oaks, California, which continues to operate it as a wholly-owned subsidiary focused on genomics research.

Research and discoveries

The core of its scientific work involves conducting genome-wide association studies on tens of thousands of volunteers from Iceland and other populations. This research has identified numerous genetic variants associated with risks for diseases such as Alzheimer's disease, coronary artery disease, type 2 diabetes, and various cancers. A landmark achievement was the discovery of the BRCA2 gene mutation's role in breast cancer, which had a profound impact on clinical genetics. Its scientists have also published extensively on the genetic underpinnings of traits like schizophrenia, bipolar disorder, and osteoporosis in prestigious journals like Nature and Science. Furthermore, its work in human evolution has utilized ancient DNA from archaeological sites across Iceland to trace population migrations and history.

Business model and operations

Its primary business model involves the discovery of genetic targets for drug development and the creation of diagnostic tests, serving the pharmaceutical industry. As a subsidiary of Amgen, it contributes to the parent company's drug discovery pipeline by identifying novel therapeutic targets and validating existing ones. The company also operates a clinical laboratory that offers genetic risk assessments for diseases directly to consumers and through healthcare providers. Its operations are supported by a large biobank containing DNA samples, phenotypic data, and digital health records from a significant portion of the Icelandic populace, forming one of the most detailed resources for genetic research in the world.

Impact and controversies

The company has had a substantial impact on modern biomedical science, providing a blueprint for large-scale population genomics projects like the UK Biobank and the All of Us Research Program in the United States. Its discoveries have been instrumental in shifting medical research towards a more genetic and preventative framework. However, its activities have sparked major ethical and legal debates concerning informed consent and the commercialization of national health data. The proposed Health Sector Database Act faced strong opposition from groups like Mannvernd, an Icelandic association for ethics in science and medicine, and was ultimately deemed unconstitutional by the Supreme Court of Iceland in 2003 over privacy concerns. These debates have influenced global discourse on biobank ethics and data protection laws, including the General Data Protection Regulation in the European Union.

Data and privacy

Its research is predicated on accessing and analyzing a vast collection of genotypic and phenotypic data, linked to the extensive genealogical records maintained by the National Archives of Iceland. The company employs a system of presumed consent, where individuals are included in studies unless they explicitly opt-out, a model that has been scrutinized internationally. All research is overseen by the Icelandic Data Protection Authority and the National Bioethics Committee. Data security is managed through stringent de-identification and encryption protocols. The legal and ethical framework governing its work has evolved through landmark cases, balancing the promise of scientific progress against the fundamental right to genetic privacy.

Category:Biotechnology companies Category:Genomics companies Category:Companies based in Reykjavík Category:1996 establishments in Iceland